Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adial Pharmaceuticals ( (ADIL) ) has shared an update.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in genetically targeted therapies for addiction, is advancing its lead candidate AD04 for Alcohol Use Disorder into a new Phase 3 program. The company is building on encouraging ONWARD Phase 3 data and a proprietary genetic test, while exploring broader indications such as opioid use disorder, gambling, and obesity.
On February 23, 2026, Adial received notice from Nasdaq that it had regained compliance with the exchange’s $1.00 minimum bid price rule after its shares closed at or above that level for ten consecutive business days from February 6 to February 20, 2026. The resolution of this listing issue, announced publicly on February 24, 2026, removes a key overhang on the stock as management highlights advanced strategic partnering discussions to support AD04’s next development phase and potential commercialization.
The most recent analyst rating on (ADIL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Neutral.
The score is held down primarily by weak fundamentals (no revenue, ongoing losses, and persistent cash burn) and a bearish technical backdrop (below key moving averages with negative MACD). A modest positive offset comes from a low-leverage balance sheet and the recent $2.86M financing that supports near-term liquidity.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for addictions and related disorders. Its lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder in heavy drinking patients, with Phase 3 development plans guided by a proprietary diagnostic genetic test.
The company’s prior ONWARD Phase 3 trial for AD04 showed promising reductions in heavy drinking without significant safety or tolerability concerns. Adial also believes AD04 may have potential applications in other addictive disorders, including opioid use disorder, gambling, and obesity, positioning the firm within a niche of precision addiction therapeutics.
Average Trading Volume: 27,266
Technical Sentiment Signal: Sell
Current Market Cap: $2.99M
For a thorough assessment of ADIL stock, go to TipRanks’ Stock Analysis page.